Últimas noticias sobre Cytek Biosciences (NASDAQ:CTKB) Bolsa

Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Cytek Biosciences Inc

LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.15 by 13.33 percent. The company reported quarterly sales of $168.599 million which beat the analyst consensus estimate of $167.472 million by 0.67 percent. This is a 0.79 percent increase over sales of $167.274 million the same period last year.

Earnings

Earnings Beats

News

LegalZoom.com Q3 2024 Adj. EPS $0.17 Beats $0.15 Estimate, Sales $168.599M Beat $167.472M Estimate

Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.07) by 128.57 percent. The company reported quarterly sales of $11.776 million which beat the analyst consensus estimate of $10.479 million by 12.38 percent. This is a 28.28 percent increase over sales of $9.180 million the same period last year.

Laird Superfood Q3 2024 Adj. EPS $0.02 Beats $(0.07) Estimate, Sales $11.776M Beat $10.479M Estimate

Sports betting and online gaming company DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) could highlight early results from the 2024 NFL season and new state legalizations when the company reports third-quarter financial results Thursday<a href="https://www.benzinga.com/earnings"> after market close.</a>
Earnings Estimates: Analysts expect the company to report third-quarter revenue of $1.11 billion, up from last year's third-quarter total of $789.96 million according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company missed analyst estimates for revenue for the second quarter and two of the past three quarters, but has beaten analyst estimates for revenue in eight of the last 10 quarters overall.
Analysts expect DraftKings to report a loss of 42 cents per share in the third quarter, compared to a loss of 35 cents per share in last year's third quarter. The company has beaten analyst estimates for earnings per share in 10 straight quarters.
Read Also: <a href="https://www.benzinga.com/general/politics/24/11/41725070/draftkings-offers-10k-in-prizes-for-2024-election-predictions-harris-trump-swing-state-performan">DraftKings Offers $10K In Prizes For 2024 Election Predictions: Harris, Trump Swing State Performance Among Key Questions</a>
What Analysts Are Saying: Strong market share in the sports betting space and the potential to surprise with updated financial guidance has Bank of America analyst Shaun C. Kelley bullish on DraftKings <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41589183/draftkings-stock-to-hit-new-52-week-highs-bullish-analyst-on-2025-guidance-upside-o">ahead of the earnings report.</a>
The analyst, who has a Buy rating and $50 price target, recently said revenue flowthrough for the second half of the fiscal year could be better than expected and "protect" EBITDA for fiscal 2024.
"We expect top-line growth in the fourth quarter to come in slightly below guidance driven by unfavorable hold and challenging iGaming comps," Kelley said.
The analyst said DraftKings could also show its hold expansion similar to peer FanDuel with lower promotional spending activity.
Concerns for DraftKings in the third quarter include slower app downloads and unfavorable NFL game outcomes, Kelley added.
A near duopoly of the online sports betting space for DraftKings and FanDuel owner Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40985921/flutter-analyst-sees-significant-earnings-power-with-growing-duopoly-sports-betting">was highlighted by </a>Needham analyst Bernie McTernan recently.
McTernan said the total addressable market size of the U.S. online sports betting market could "continue to surprise to the upside."
&#8220;Scale and commitment to product leadership from FanDuel and DKNG likely keeps the OSB market dominated by these two players," McTernan said.
A Needham survey revealed that sports bettors primarily use FanDuel and DraftKings.
&#8220;We think share can continue to ebb and flow between FanDuel and DKNG as we do not see a physical network effect in OSB meaning there is not a structural reason for dominant market share leader like digital marketplaces.&#8221;
McTernan said unless the market structure in the U.S. changes, it&#8217;s &#8220;FanDuel and DKNG at the top and then everyone else.&#8221;
FanDuel (37.8%) and DraftKings (34.8%) had a combined 73% market share in 2023. BetMGM ranks a distant third at 8.6% market share.
In the second quarter of 2024, FanDuel had a market share of 37.3% with DraftKings at 37.0%. Both BetMGM and fourth-place Caesars had lower market share in the first two quarters of 2024 compared to 2023.
Key Items to Watch: DraftKings quarterly financial results come after the start of the 2024 NFL season, which is one of the most bet on sports in the U.S. and a key to revenue and earnings for the company in the fourth quarter.
Guidance from the company and early commentary on the NFL season will be closely watched by investors.
The company<a href="https://www.benzinga.com/news/earnings/24/08/40116073/draftkings-q2-earnings-highlights-sports-betting-company-launches-1-billion-buyback-misses-on-reven"> announced an inaugural</a> $1 billion share buyback in the second quarter. Investors and analysts will be watching to see if any shares were bought during the third quarter.
DraftKings acquisition of Jackpocket led to lower average revenue per monthly unique paying customer in the second quarter and could be an area to watch for investors and analysts.
As of July 25, DraftKings is live with mobile sports betting in 25 states and Washington, D.C., representing 49% of the U.S. population.
The company is live with iGaming in five states.
On Tuesday, voters in Missouri approved sports betting, becoming the 39th state to legalize. There is no current timetable on when the state will be live, but DraftKings and FanDuel supported the ballot proposal.
Missouri is the 18th most populous state and fourth-largest state that has not yet legalized sports betting, according to a report from <a href="https://www.sportico.com/business/sports-betting/2024/missouri-sports-betting-ballot-measure-caesars-draftkings-fanduel-1234803926/">Sportico</a>.
DraftKings previously said there were 10 jurisdictions representing 12% of the U.S. population that have introduced legislation or introduced a bill for a referendum to legalize mobile sports betting.
An update on the timetable in Missouri and where other states stand could come from the company on Thursday.
DKNG Price Action: DraftKings stock was up 4.94% to $38.25 on Wednesday at market close versus a 52-week trading range of $28.69 to $49.57. DraftKings stock is up 14% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41402089/goldman-sachs-highlights-20-top-short-squeeze-opportunities-for-q3-earnings-season">Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Sports Betting

Previews

Analyst Ratings

Trading Ideas

DKNG

FLUT

DraftKings Q3 Earnings Highlights: NFL In Focus, Will Missouri Legalization Factor Into Guidance?

CDMO

Trading Halt: Halt status updated at 6:30:00 PM ET: Quotation Resumption: News and Resumption Times

Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.14) by 164.29 percent. This is a 164.29 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $68.638 million which missed the analyst consensus estimate of $70.514 million by 2.66 percent. This is a 9.62 percent increase over sales of $62.612 million the same period last year.

Earnings Misses

Redwire Q3 2024 GAAP EPS $(0.37) Misses $(0.14) Estimate, Sales $68.638M Miss $70.514M Estimate

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.07 by 42.86 percent. This is a 42.86 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $58.004 million which beat the analyst consensus estimate of $57.150 million by 1.49 percent. This is a 17.41 percent increase over sales of $49.402 million the same period last year.

Viemed Healthcare Q3 2024 GAAP EPS $0.10 Beats $0.07 Estimate, Sales $58.004M Beat $57.150M Estimate

Genworth Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNW#NYSE">GNW</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.19 by 42.11 percent. This is a 22.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported $1.88 billion in sales this quarter. This is a 2.68 percent increase over sales of $1.83 billion the same period last year.

Genworth Finl Q3 Adj $0.11 Misses $0.19 Estimate, Sales $1.88B Up From $1.83B YoY

Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.89 by 20.22 percent. The company reported quarterly sales of $417.600 million which missed the analyst consensus estimate of $438.700 million by 4.81 percent. This is a 0.29 percent decrease over sales of $418.800 million the same period last year.

PKOH

Park-Ohio Hldgs Q3 2024 Adj. EPS $1.07 Beats $0.89 Estimate, Sales $417.600M Miss $438.700M Estimate

Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) reported quarterly losses of $(2.22) per share which missed the analyst consensus estimate of $0.05 by 4540 percent. The company reported quarterly sales of $1.089 billion which missed the analyst consensus estimate of $1.128 billion by 3.44 percent. This is a 3.29 percent decrease over sales of $1.126 billion the same period last year.

LILA

Liberty Latin America Q3 2024 GAAP EPS $(2.22) Misses $0.05 Estimate, Sales $1.089B Miss $1.128B Estimate

Gold production in 2025 is expected to increase significantly relative to 2024 as a result of the scheduled mining and processing of higher-grade ore from the Fekola and Cardinal pits made accessible by the meaningful stripping campaign that has been undertaken throughout 2024, the expected full year of contribution from Fekola Regional, which is anticipated to contribute between 80,000 and 100,000 ounces of additional production, and commencement of mining the higher-grade Fekola underground (subject to receipt of necessary permits for Fekola Regional and Fekola underground).

Guidance

B2Gold Expects Total Gold Production For 2024 To Be Towards Low End Of Guidance Range Of 800,000 - 870,000 Ounces; Expects Gold Production In 2025 To Increase Significantly Relative To 2024

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) raises FY2024 sales outlook from $200.00 million-203.00 million to $202.00 million-204.00 million.

KIDS

OrthoPediatrics Raises FY2024 Sales Guidance from $200.00M-203.00M to $202.00M-204.00M

Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.35 by 17.14 percent. This is a 32.26 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $178.69 million which missed the analyst consensus estimate of $185.47 million by 3.66 percent. This is a 6.40 percent increase over sales of $167.94 million the same period last year.

Montrose Environmental Gr Q3 Adj $0.41 Beats $0.35 Estimate, Sales $178.69M Miss $185.47M Estimate

B2Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.05 by 60 percent. This is a 60 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $448.23 million which beat the analyst consensus estimate of $444.81 million by 0.77 percent. This is a 6.21 percent decrease over sales of $477.89 million the same period last year.

B2Gold Q3 2024 Adj EPS $0.02 Misses $0.05 Estimate, Sales $448.23M Beat $444.81M Estimate

Lower than expected gold production at Candelaria and slower ramp-ups at newly contributing mines have resulted in fewer Precious Metal GEOs than originally anticipated. In addition, record gold prices in the current year have impacted the conversion of non-gold revenue into GEOs.&nbsp;

Franco-Nevada Expects Full-year 2024 Revenue To Be $1.05B - $1.15B, Est $1.127B

Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) reported quarterly losses of $(1.62) per share which missed the analyst consensus estimate of $(1.47) by 10.2 percent. This is a 57.28 percent decrease over losses of $(1.03) per share from the same period last year. The company reported quarterly sales of $867.700 million which missed the analyst consensus estimate of $887.550 million by 2.24 percent. This is a 1.29 percent decrease over sales of $879.000 million the same period last year.

Trinseo Q3 2024 Adj. EPS $(1.62) Misses $(1.47) Estimate, Sales $867.700M Miss $887.550M Estimate

UMH Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMH#NYSE">UMH</a>) reported quarterly earnings of $0.24 per share which met the analyst consensus estimate. This is a 9.09 percent increase over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $60.671 million which beat the analyst consensus estimate of $58.816 million by 3.15 percent. This is a 8.26 percent increase over sales of $56.044 million the same period last year.

UMH Properties Q3 2024 FFO $0.24, Inline, Sales $60.671M Beat $58.816M Estimate

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze.
The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Net Income Boosted By Adjusted Expenses</h3>
The company generated net income in the range of $430 to $550 million, increasing its GAAP EPS guidance to between $6.70 and $8.50. Jazz also adjusted its R&amp;D expense forecast, reflecting strategic prioritization within its pipeline, notably the anticipated fourth-quarter launch of zanidatamab for 2L BTC, a significant step in oncology.
<h3 class="wp-block-heading">Liquidity And Debt Management</h3>
With $2.6 billion in cash and investments, Jazz maintains $500 million in undrawn credit. Jazz repaid $575 million in senior notes due 2024, illustrating its disciplined debt management. The company <a href="https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2024-financial-results-302297961.html">reported</a> that its financial and product strategies are expected to drive growth in critical therapeutic areas, enhancing long-term shareholder value.
Price Action: Jazz Pharmaceuticals shares remained relatively stable, closing at $111.55 with a slight gain of 0.11%
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/11/41774692/aurora-cannabis-reports-strong-q2-growth-driven-by-international-medical-marijuana-sales"> Aurora Cannabis Reports Strong Q2 Growth Driven By International Medical Marijuana Sales</a>

Cannabis

Markets

JAZZ

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares are tumbling in Wednesday&#8217;s after-hours session in the wake of the company&#8217;s third-quarter financial results. Wolfspeed announced initiatives to streamline its cost structure. Here&#8217;s a <a href="https://www.benzinga.com/quote/WOLF">rundown of the report</a>.
<ul>
<li>Q1 Revenue: $194.7 million, versus estimates of $200.39 million</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: Loss of 91 cents, versus estimates for a loss of $1.</li>
</ul>
&#8220;To drive operational improvements, we are taking action to enhance efficiency, align our business with current market conditions and become the first silicon carbide company to transition to pure-play 200-millimeter. The transition to a fully 200-millimeter platform allows us to take further initiatives to streamline our cost structure, including closing our manual Durham 150-millimeter Fab, other manufacturing footprint rationalization, and reducing our workforce,&#8221; said Gregg Lowe, CEO of Wolfspeed.
Wolfspeed ended the quarter with approximately $1.7 billion in cash and investments. The company also noted it has access to up to $2.5 billion in incremental funding to support its U.S. capacity expansion plans.
The company said it expects its cost-cutting initiatives to result in approximately $200 million in annual cash savings. 
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/11/41791722/applovin-stock-soars-after-q3-earnings-report-revenue-beat-eps-beat-strong-software-platform-growth">Applovin Stock Soars After Q3 Earnings Report: Revenue Beat, EPS Beat, Strong Software Platform Growth</a>
Q2 Guidance: Wolfspeed expects second-quarter revenue of $160 million to $200 million versus estimates of $214.58 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company anticipates a second-quarter loss of 89 cents to $1.14 per share versus estimates for a loss of 90 cents per share.
&#8220;We delivered 2.5 times year-over-year growth in our automotive business in the&nbsp;first quarter, and we expect our EV revenue to continue to grow throughout calendar 2025, as the total number of car models using a Wolfspeed silicon carbide solution in the power train increased by 4x from 2023 to 2024 and is expected to grow by another approximately&nbsp;75%&nbsp;year over year in 2025,&#8221; Lowe said.
&#8220;We also remain confident in the long-term fundamentals of our industrial and energy business. Importantly, we believe the secular trends and long-term growth drivers for our core end markets remain intact, and we expect the actions we are taking today will allow us to become a more efficient and agile organization positioned to capture the long-term growth opportunities ahead.&#8221;
WOLF Price Action: <a href="http://benzinga.com/quote/wolf">Wolfspeed shares</a> were down 18.67% after hours at $11.15 at the time of publication Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Wolfspeed.

After-Hours Center

Movers

WOLF

Wolfspeed Stock Is Falling After The Bell: What's Going On?

Workiva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WK#NYSE">WK</a>) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.23 by 8.7 percent. This is a 132.31 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $185.621 million which beat the analyst consensus estimate of $182.577 million by 1.67 percent. This is a 17.35 percent increase over sales of $158.175 million the same period last year.

Workiva Q3 2024 Adj. EPS $0.21 Misses $0.23 Estimate, Sales $185.621M Beat $182.577M Estimate

In 2025, as a result of a softer oil price outlook, APA plans to reduce capital to $2.5 to $2.6 billion, of which, $200 million is allocated to Suriname development activity and $100 million to other exploration, primarily in Alaska.&nbsp;
At this investment level, the company expects to run an eight-rig program in the Permian Basin and a 12-rig program in Egypt, which includes one rig dedicated to natural gas following the signing of a new gas pricing agreement.&nbsp;
The company expects this program will roughly sustain adjusted oil production in the U.S. and Egypt, while delivering mid-single digit adjusted BOE growth. &nbsp; &nbsp;

APA Expects Total Q4 Production On BOE Basis To Be The Highest Of The Year Despite Ongoing Curtailments In  Permian Basin In Response To Weak Regional Natural Gas Prices

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Cytek Biosciences (CTKB – Research Report), with a price...

Cytek Biosciences (CTKB) Receives a Buy from Piper Sandler

Piper Sandler analyst David Westenberg maintained a Buy rating on Cytek Biosciences (CTKB – Research Report) today and set a price target of $8.00....

Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)

Cytek Biosciences ( ($CTKB) ) has shared an announcement. Paul Christopher Williams has resigned as the Chief Operating Officer of Cytek Bioscience...

Cytek Biosciences COO Resigns, Signaling Leadership Changes

Warning: CTKB is at high risk of performing badly

Reports Q3 revenue $51.5M, consensus $50.7M."We delivered solid year-over-year revenue growth in the third quarter of 2024 despite persistent indus...

Cytek Biosciences reports Q3 EPS 1c, consensus (2c)

Cytek Biosciences (CTKB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith ...

Positive Outlook and Buy Rating for Cytek Biosciences Amid Strong International Performance and Strategic Expansion

Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript

Cytek Biosciences, Inc. ( ($CTKB) ) has released its Q3 earnings. Here is a breakdown of the information Cytek Biosciences, Inc. presented to its i...

Cytek Biosciences' Q3 2024 Financial Highlights

Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Trump Media (DJT) jumps after Donald T...

Trump Media, broader market surge after Trump wins election: Morning Buzz

AAPL

AVDX

CBOE

CELH

CTKB

EXAS

FIVE

HNDAF

HNHAF

HNHPF

IRBT

NTDOF

NTDOY

PACS

PLNT

RVLV

SMCI

SNOW

STLA

TEVA

TNGX

TRMB

Press Releases

Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024

General

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

Cytek Biosciences Reports Second Quarter 2024 Financial Results

Cytek Biosciences to Participate in Upcoming Investor Conferences

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Management

Cytek Announces Resignation of Chief Operating Officer Chris Williams

Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

Cytek Biosciences Reports Third Quarter 2024 Financial Results

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Akoya Biosciences

Azenta

BioLife Solns

ChromaDex

Codexis

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology

OmniAb

Pacific Biosciences of California, Inc. - Common Stock

Comments

Cytek Biosciences

Noticias

Últimas noticias sobre Cytek Biosciences (NASDAQ:CTKB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL